Penumbra (PEN) Return on Capital Employed (2015 - 2026)
Penumbra's (PEN) quarterly Return on Capital Employed came in at 11.34% in Q1 2026, up 866.0% year-on-year from 1.17% in Q1 2025, and down 4.02% on a QoQ basis from 11.81% in Q4 2025.
Penumbra (PEN) Return on Capital Employed (2015 - 2026) Analysis & Trends
Penumbra (PEN) has 12 years of Return on Capital Employed data on file, last reported at 11.34% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 866.0% year-over-year to 11.34% in Q1 2026; TTM through Mar 2026 was 11.34%, a 866.0% increase from a year earlier, with the FY2025 full-year figure at 12.64%, up 1197.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 11.34%, down from 11.81% in the prior quarter.
- Over the last five years, Return on Capital Employed for PEN reached as high as 11.81% in Q4 2025 and fell as low as 3.27% in Q3 2022.
- Historically, Return on Capital Employed has averaged 3.39% across 5 years, with a median of 2.67% in 2025.
- Across the five-year window, Return on Capital Employed tumbled 471 bps in 2024 and surged 1230 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 0.51% in 2022, then soared by 967 bps to 5.4% in 2023, then plunged by 87 bps to 0.69% in 2024, then soared by 1616 bps to 11.81% in 2025, then fell by 4 bps to 11.34% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 11.34% in Q1 2026, 11.81% in Q4 2025, and 11.22% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 11.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.34% |
| Dec 31, 2025 | 11.81% |
| Sep 30, 2025 | 11.22% |
| Jun 30, 2025 | 10.79% |
| Mar 31, 2025 | 2.67% |
| Dec 31, 2024 | 0.69% |
| Sep 30, 2024 | 0.11% |
| Jun 30, 2024 | -1.51% |
| Mar 31, 2024 | 5.49% |
| Dec 31, 2023 | 5.40% |
| Sep 30, 2023 | 3.32% |
| Jun 30, 2023 | 2.85% |
| Mar 31, 2023 | 1.47% |
| Dec 31, 2022 | 0.51% |
| Sep 30, 2022 | -3.27% |
| Jun 30, 2022 | -3.03% |
| Mar 31, 2022 | -2.19% |
| Dec 31, 2021 | -0.76% |
| Mar 31, 2021 | -3.62% |
| Dec 31, 2020 | -5.48% |